NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT06683846 2025-08-24Ivonescimab in the Treatment of Multiple Advanced TumorsFudan UniversityPhase 2 Recruiting400 enrolled